Alerta

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Resumen de: US20260055183A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

Crohn disease auxiliary prediction method and device based on machine learning

Resumen de: CN121565478A

The invention relates to a Crohn disease auxiliary prediction method based on machine learning. The method comprises the following steps: obtaining related prediction data of a user; whether missing items exist in the user related prediction data is judged, if yes, an alarm is given to remind a user to supplement, if the user confirms that supplement cannot be carried out, self-adaptive complementation is carried out, and finally to-be-predicted data is formed; inputting the to-be-predicted data into a pre-established Crohn disease auxiliary prediction model, and outputting a prediction result by the Crohn disease auxiliary prediction model; the Crohn disease auxiliary prediction model is constructed based on an XGBoost model; and visually displaying the prediction result to inform a user. According to the method, when the data input by the user is missing, the user can be reminded to supplement, if the data cannot be supplemented, self-adaptive complementation is carried out, the prediction accuracy of the model is improved, Crohn disease risk prediction can be carried out according to the existing indexes of the patient, the user can conveniently find related risks in time, and the user experience is improved. And the diagnosis and treatment efficiency of the user is improved.

基于荧光探针的ATP水解酶抗体高效筛选法

Resumen de: CN121559077A

本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。

潰瘍性大腸炎に関与する遺伝子の抗ＩＬ－２３Ｐ１９抗体調節

Resumen de: US2024254217A1

The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.

Application of Slc36a1 agonist in preparation of medicine for preventing and/or treating colitis

Resumen de: CN121512985A

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

Anti-TL1A antibody therapy methods

Resumen de: CN121532526A

The present disclosure provides methods and compositions for determining the risk of a patient unresponsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody, and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

BIOMARKERS OF INFLAMMATORY BOWEL DISEASES (Machine-translation by Google Translate, not legally binding)

Resumen de: ES3055703A1

Biomarkers of inflammatory bowel diseases. The present invention relates to a method for early determination of whether a subject has an inflammatory bowel disease, comprising determining the expression product level of at least one biomarker, from a biological sample of a subject, selected from: ATRN, PRDX4, MOAB and AZU1. (Machine-translation by Google Translate, not legally binding)

PROPHYLACTIC OR THERAPEUTIC AGENT FOR CROHN'S DISEASE AND METHOD FOR EXAMINING CROHN'S DISEASE

Resumen de: WO2026034527A1

Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.

METHODS OF CLASSIFYING AND TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: WO2024206308A2

Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.

Multi-index content determination method of fructus aurantii immaturus and rhizoma atractylodis bowel-relaxing granules

Resumen de: CN121499685A

The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.

METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST

Resumen de: EP4417707A2

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis

Resumen de: CN121472476A

The invention discloses a citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis. According to the invention, a genome typing technology in a whole genome range is adopted, and a set of discrimination system capable of accurately identifying real hybrid offspring is established through high-density SNP (Single Nucleotide Polymorphism) marker analysis and an IBD (Identity by means of an algorithm. The method breaks through the limitation of a traditional method on hybrid filial generation identification, and provides reliable technical support for breeding practice.

BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB

Resumen de: WO2026027676A1

Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.

COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASE

Resumen de: US20260036584A1

This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.

BIOMARKERS FOR DETERMINING TREATMENT OF ULCERATIVE COLITIS WITH FILGOTINIB

Resumen de: WO2026027669A1

Filgotinib or a pharmaceutically acceptable salt thereof for use in a method of treating ulcerative colitis is provided, along with methods of deciding whether to continue treating ulcerative colitis in a patient with filgotinib or a pharmaceutically acceptable salt. The treatments are based on the assessment of the levels of certain predictive biomarkers in the patient having ulcerative colitis.

琥珀酸对坏死性小肠结肠炎影响机制的研究方法

Resumen de: CN121454070A

本发明公开了琥珀酸对坏死性小肠结肠炎影响机制的研究方法，涉及生物医学研究技术领域；包括如下步骤：S1：动物模型建立：选择新生小鼠，随机分为4组；S2：干预周期：持续处理3‑5天，每日记录体重、存活率及存活状态；S3：样本采集：处死小鼠，取肠组织，分装用于不同检测；S4：多维度检测；S5：数据分析：整合表型、病理、分子数据，验证琥珀酸‑SUCNR1轴的功能。本发明构建了完整的研究琥珀酸‑SUCNR1轴在坏死性小肠结肠炎中作用机制的技术体系，通过动物模型构建、分子机制验证和病理评估的有机结合，形成了从现象观察到机制阐明的完整证据链，确保研究结论的可靠性。

双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用

Resumen de: CN121445742A

本发明涉及双氢麦角胺在制备预防和/或治疗炎症性肠病的药物中的应用。本发明在炎症性肠病模型中验证得出一种全新的作用机制：炎症条件下TRIM25会介导LSD1的泛素化降解，引起肠上皮组织代谢紊乱加剧炎症。本发明通过预测TRIM25和LSD1结合的结构信息，使用虚拟药物筛选，筛到了双氢麦角胺小分子化合物，其可很好地占据TRIM25和LSD1互作的结合位点，抑制TRIM25和LSD1的互作，从而抑制LSD1的降解；在DSS诱导的小鼠结肠炎模型中，双氢麦角胺能缓解肠上皮因代谢紊乱造成的炎症激活，很好地缓解炎症性肠病的症状。上述过程作用机制明确，效果显著，实现了双氢麦角胺在治疗炎症性肠病方面的老药新用，具有较高的临床应用价值。

Cistanche deserticola polysaccharide as well as preparation method and application thereof

Resumen de: CN121426979A

The invention belongs to the technical field of biological medicine, and particularly discloses cistanche polysaccharide as well as a preparation method and application thereof. The preparation method comprises the following steps: S1, washing, drying and crushing fresh cistanche, and removing impurities with absolute ethyl alcohol to obtain a reactant; s2, putting the reactant obtained in the step S1 into hot water for extraction, and adding absolute ethyl alcohol for precipitation after concentration to obtain crude polysaccharide; s3, adding a chloroform-n-butyl alcohol solution for deproteinization, and removing pigments by using macroporous resin; s4, chromatographic purification is conducted through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence, polysaccharide components are collected, dialysis and freeze-drying are conducted, and the cistanche deserticola polysaccharide is obtained. The cistanche deserticola polysaccharide has a remarkable anti-inflammatory effect, can improve the richness and uniformity of intestinal flora, optimize flora balance and maintain the barrier function of the intestinal tract, and has a wide prospect in preparation of medicines for preventing or treating colitis.

CHEMICAL PROBES FOR MICROBIAL MUCIN DEGRADERS IN THE GUT MICROBIOME

Resumen de: WO2026024847A2

Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.

ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF

Resumen de: EP4684799A2

Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Joint inspection kit for predicting endoscopic response of inflammatory bowel disease and prediction method and application thereof

Resumen de: CN121410275A

The invention relates to a joint detection kit for predicting endoscopic response of inflammatory bowel disease in the technical field of medical examination, and solves the technical problem that the existing single biomarker is limited in detection sensitivity and specificity. Comprising an excrement calprotectin detection reagent and an excrement lactoferrin detection reagent, a monoclonal antibody sandwich ELISA method is adopted for calprotectin detection, and the detection range is 10-3000 mu g/g; the lactoferrin is detected by adopting a chemiluminescence immunoassay method, and the detection range is 5-500mu g/g. An endoscopic response prediction scoring model is established based on calprotectin concentration X and lactoferrin concentration Y: prediction score = alpha * ln (X + 1) + beta * ln (Y + 1) + clinical correction factor, alpha is 0.65-0.75, beta is 0.45-0.55, and the clinical correction factor integrates C-reactive protein, fecal occult blood and patient age. Compared with single detection, the sensitivity is improved to 85%-88%, and the specificity is improved to 83%-86%.

Application of soluble protein B7-H5 in preparation of Crohn disease detection preparation

Resumen de: CN121385324A

The invention belongs to the field of biological medicine, and particularly relates to application of soluble B7-H5 in preparation of a Crohn disease detection reagent. According to the invention, the level of soluble B7-H5 (sB7-H5) in serum of a patient suffering from Crohn's disease (CD) is deeply analyzed by using an ELISA (Enzyme-Linked Immunosorbent Assay) technology. Studies find that sB7-H5 in serum of a CD patient is remarkably and highly expressed and is positively correlated with a disease activity index (CDAI). Further experimental verification shows that blocking of B7-H5 can promote polarization of inflammatory macrophages. Based on the discoveries, the invention provides the application of the serum B7-H5 as the molecular marker of the Crohn's disease to development of products for detection, prognosis or treatment of the Crohn's disease. The molecular marker can be in a soluble B7-H5 gene or protein form. The invention also shows that the B7-H5 can be used as a potential target for developing the medicine for preventing and treating the Crohn disease, and has important clinical application value.

CCDC71L在诊断及治疗放射性肠炎中的应用

Resumen de: CN119433017A

The invention discloses an application of CCDC71L in diagnosis and treatment of radiation enteritis, and provides an application of a reagent for detecting the expression level of the CCDC71L in preparation of a product for diagnosing radiation enteritis and an application of an inhibitor of the CCDC71L in preparation of a medicine for treating radiation enteritis. The invention further provides a method for screening candidate drugs for treating or preventing radiation enteritis and a method for inhibiting the expression level of inflammatory factors in macrophages. Experiments prove that the CCDC71L can realize diagnosis of radiation enteritis, and discovers that inhibition of the CCDC71L can inhibit infiltration and polarization of macrophages so as to inhibit radiation-induced inflammatory reaction, and the CCDC71L marker provided by the invention provides a new idea for diagnosis and treatment of radiation enteritis, and has a wide application prospect.

SEROLOGY REPERTOIRE FOR THE DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE

Resumen de: WO2026020057A1

This disclosure provides for method for the diagnosis, prognosis and treatment of inflammatory bowel disease (IBD) and clinical subtypes of IBD in a subject by detecting the presence or level of one or more immune responses to self and microbial antigens in a sample from a subject.

METHOD FOR MONITORING AND EVALUATION OF BOWEL HEALTH IN PREMATURE NEWBORNS

Nº publicación: US20260022426A1 22/01/2026

Solicitante:

CHOUTHAI NITIN SHASHIKANT [US]
Chouthai Nitin Shashikant

Resumen de: US20260022426A1

Disclosed is a method for monitoring and evaluation of bowel health in premature newborns. The method involves collecting stool/fecal samples from premature newborns/babies and processing the sample using microbiomics, automated cell counting, flowcytometry, and RT PCR analysis using specific gene signature or RNA transcriptomics analysis to determine risk of necrotizing enterocolitis. The method allows evaluation and tracking of gut health without needing to draw a blood test and is a non-invasive method. The method diagnoses and prevents bowel inflammation, infection and necrotizing enterocolitis (NEC) that facilitates initiation of prompt therapy to limit morbidity and mortality in premature babies. The method facilitates early management of signs of NEC thereby helping to save lives of premature babies and infants having low birth weight.